NLRP3 and type 2 diabetes mellitus: Similarly, in mice with progressive T2DM (BTBR ob/ob), dapagliflozin decreases the myocardial expression of NLRP3, TNFα, and caspase-1, ameliorating the diabetic cardiomyopathy [224].